REFRACTORY CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE
Clinical trials for REFRACTORY CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE trials appear
Sign up with your email to follow new studies for REFRACTORY CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Target immune therapy enters human trials for aggressive blood cancers
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new type of CAR-T cell therapy designed to attack three different proteins (CD19, CD20, and CD22) found on cancer cells. It is for adults with certain aggressive blood cancers like non-Hodgkin lymphoma, acute lymphob…
Matched conditions: REFRACTORY CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Engineered immune cells target Leukemia's return
Disease control Recruiting nowThis early-stage trial is testing a new cell therapy for children and adults whose leukemia has come back or persists after a donor stem cell transplant. Doctors take immune cells (T cells) from the original donor, genetically modify them to better recognize and attack the patien…
Matched conditions: REFRACTORY CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC